Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223–249. https://doi.org/10.1146/annurev-pathol-042020-042741

Article  CAS  PubMed  Google Scholar 

Wang SJ, Dougan SK, Dougan M (2023) Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer 9(7):543–553. https://doi.org/10.1016/j.trecan.2023.04.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer (Oxford, England : 1990) 73:1–8. https://doi.org/10.1016/j.ejca.2016.12.001

Article  CAS  Google Scholar 

Farina A, Villagrán-García M, Vogrig A, Zekeridou A, Muñiz-Castrillo S, Velasco R et al (2024) Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol 23(1):81–94. https://doi.org/10.1016/s1474-4422(23)00369-1

Article  CAS  PubMed  Google Scholar 

Picca A, Berzero G, Bihan K, Jachiet V, Januel E, Coustans M et al (2021) Longitudinally extensive myelitis associated with immune checkpoint inhibitors. Neurol (R) Neuroimmunol Neuroinflammation 8(3). https://doi.org/10.1212/nxi.0000000000000967

Chatterton S, Xi S, Jia JX, Krause M, Long GV, Atkinson V et al (2023) Case series: immune checkpoint inhibitor-induced transverse myelitis. Front Neurol 14:1130313. https://doi.org/10.3389/fneur.2023.1130313

Article  PubMed  PubMed Central  Google Scholar 

Hirano S, Kojima A, Nakayama Y, Takeda T, Kishimoto T, Takahashi T et al (2022) A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study. BMC Neurol 22(1):483. https://doi.org/10.1186/s12883-022-02987-6

Article  PubMed  PubMed Central  Google Scholar 

Narumi Y, Yoshida R, Minami Y, Yamamoto Y, Takeguchi S, Kano K et al (2018) Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. BMC Cancer 18(1):95. https://doi.org/10.1186/s12885-018-3997-2

Article  PubMed  PubMed Central  Google Scholar 

Shimada T, Hoshino Y, Tsunemi T, Hattori A, Nakagawa E, Yokoyama K et al (2020) Neuromyelitis optica spectrum disorder after treatment with pembrolizumab. Mult Scler Relat Disord 37:101447. https://doi.org/10.1016/j.msard.2019.101447

Article  PubMed  Google Scholar 

Nasralla S, Abboud H (2020) Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? Insights from checkpoint inhibitor immune-related adverse events. Mult Scler Relat Disord 46:102451. https://doi.org/10.1016/j.msard.2020.102451

Article  PubMed  Google Scholar 

Weiss D, Cantré D, Zettl UK, Storch A, Prudlo J (2022) Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab. J Neurol 269(5):2778–2780. https://doi.org/10.1007/s00415-021-10913-y

Article  CAS  PubMed  Google Scholar 

Kunchok A, Zekeridou A, Pittock S (2020) CRMP5-IgG-associated paraneoplastic myelopathy with PD-L1 inhibitor therapy. JAMA Neurol 77(2):255–256. https://doi.org/10.1001/jamaneurol.2019.4379

Article  PubMed  Google Scholar 

O’Kane GM, Lyons TG, Colleran GC, Ahmad MW, Alken S, Kavanagh EC et al (2014) Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. Oncol Res Treat 37(12):757–760. https://doi.org/10.1159/000368316

Article  CAS  PubMed  Google Scholar 

Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16(4):589–593. https://doi.org/10.1093/neuonc/nou001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J et al (2018) Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer 6(1):83. https://doi.org/10.1186/s40425-018-0393-z

Article  PubMed  PubMed Central  Google Scholar 

Wilson R, Menassa DA, Davies AJ, Michael S, Hester J, Kuker W et al (2018) Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Ann Clin Transl Neurol 5(5):640–645. https://doi.org/10.1002/acn3.547

Article  PubMed  PubMed Central  Google Scholar 

Romeo MAL, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V et al (2019) Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. J Neurol 266(12):3163–3166. https://doi.org/10.1007/s00415-019-09562-z

Article  PubMed  Google Scholar 

Nowosielski M, De Pauli F, Iglseder S, Wagner M, Hoellweger N, Nguyen VA et al (2020) Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors. Neurol (R) Neuroimmunol Neuroinflammation 7(4):e773. https://doi.org/10.1212/nxi.0000000000000773

Article  Google Scholar 

Vickers ML, Seidl B, Bigby K, Chern B, Eriksson L, Hartnett G et al (2020) Inflammatory myeloradiculitis secondary to pembrolizumab: a case report and literature review. Case Rep Oncol Med 2020:8819296. https://doi.org/10.1155/2020/8819296

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basin S, Perrin J, Michot JM, Lambotte O, Cauquil C (2021) Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapy. Eur J Cancer (Oxford, England : 1990) 145:230–233. https://doi.org/10.1016/j.ejca.2020.12.014

Article  CAS  Google Scholar 

Charabi S, Engell-Noerregaard L, Nilsson AC, Stenör C (2021) Case report: longitudinal extensive transverse myelitis with novel autoantibodies following two rounds of pembrolizumab. Front Neurol 12:655283. https://doi.org/10.3389/fneur.2021.655283

Article  PubMed  PubMed Central  Google Scholar 

Januel E, Perol L, Arrivé L, Alamowitch S, Fain O, Mekinian A (2021) Anti-PD1-R checkpoint inhibitor related severe relapsing myelitis. Acta Neurol Belg 121(6):1855–1857. https://doi.org/10.1007/s13760-020-01434-y

Article  PubMed  Google Scholar 

Liu Q, Wang B, Zhao W (2022) MOG-IgG-associated demyelination induced by pembrolizumab treatment in a patient with malignant melanoma. Neurology 98(12):501–502. https://doi.org/10.1212/wnl.0000000000200055

Article  CAS  PubMed  Google Scholar 

Owen T, Fung AS (2022) Combination intravenous immune globulin (IVIG) and high dose steroids for treatment of immune-related myelitis in a non-small cell lung cancer patient treated with pembrolizumab and palliative radiation treatment: a case report. Clin Lung Cancer 23(8):e563–e567. https://doi.org/10.1016/j.cllc.2022.08.012

Article  CAS  PubMed  Google Scholar 

Wang L, Lou H, Li B, Li J, Yang YM (2022) Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer. Invest New Drugs 40(1):151–156. https://doi.org/10.1007/s10637-021-01154-x

Article  CAS  PubMed  Google Scholar 

Esechie A, Fang X, Banerjee P, Rai P, Thottempudi N (2023) A case report of longitudinal extensive transverse myelitis: immunotherapy related adverse effect vs. COVID-19 related immunization complications. Int J Neurosci 133(10):1120–1123. https://doi.org/10.1080/00207454.2022.2050907

Article  CAS  PubMed  Google Scholar 

Kim KH, Baek YH, Kang YW, Yoon BA, Moon SY (2023) A case of transverse myelitis following treatment with atezolizumab for advanced hepatocellular carcinoma. Korean J Gastroenterol = Taehan Sohwagi Hakhoe chi 82(1):35–39. https://doi.org/10.4166/kjg.2023.054

Article  PubMed  Google Scholar 

Lambert-Cheatham NA, Sakuru RC, Merati M, Tessema ST, Salbert LR, Ward JH et al (2023) A case of pembrolizumab-induced papillitis with transverse myelitis. J Neuro-ophthalmol Off J North Am Neuro-Ophthalmol Soc 43(4):e131–e133. https://doi.org/10.1097/wno.0000000000001427

Article  Google Scholar 

Syc-Mazurek SB, Zhao-Fleming H, Guo Y, Tisavipat N, Chen JJ, Zekeridou A et al (2024) MOG antibody-associated disease in the setting of metastatic melanoma complicated by immune checkpoint inhibitor use. Neurol(R) Neuroimmunol Neuroinflammation 11(4):e200249. https://doi.org/10.1212/nxi.0000000000200249

Article